COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment
Decentralized Trials Can Only Soften The Blow
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
You may also be interested in...
The Swiss major says operations have not faced significant disruptions from the coronavirus pandemic but recruitment of patients for new trials, including a high-profile trial of inclisiran, have been impacted.
In a podcast interview, Janet Woodcock talks about review deadlines, prioritizing pre-approval inspections, and how advisory committees could be held in an era of social distancing.
The Swiss major has been showcasing its Nerve Live data analytics platform, where staff stationed at its SENSE operations center in Basel can monitor 500 or so clinical studies to predict - and stop - potential delays.